Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Inflammation
Erschienen in: Inflammation 4/2023

21.04.2023 | REVIEW

The Crucial Roles and Research Advances of cGAS-STING Pathway in Cutaneous Disorders

verfasst von: Cong Huang, Wenting Li, Xuanyao Ren, Mindan Tang, Kaoyuan Zhang, Fan Zhuo, Xia Dou, Bo Yu

Erschienen in: Inflammation | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract—

The cGAS-STING signaling pathway senses the presence of cytosolic DNA, induces strong type I interferon responses, and enhances inflammatory cytokine production, placing it as an important axis in infection, autoimmunity, and tumor immunity. Recent studies have shown that the abnormalities and/or dysfunctions of cGAS-STING signaling are closely related to the pathogenesis of skin diseases and/or cancers. Additionally, a variety of new therapeutics targeting the cGAS-STING signaling are in development for the treatment of skin disorders. However, the precise molecular mechanisms of cGAS-STING-mediated cutaneous disorders have not been fully elucidated. In this review, we will summarize the regulatory roles and mechanisms of cGAS-STING signaling in skin disorders and recent progresses of cGAS-STING-related drugs as well as their potential clinical applications.
Literatur
1.
Hay, R.J., N.E. Johns, H.C. Williams, et al. 2014. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. The Journal of Investigative Dermatology 134 (6): 1527–1534.PubMedCrossRef
2.
Karimkhani, C., R.P. Dellavalle, L.E. Coffeng, et al. 2017. Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatology 153 (5): 406–412.PubMedPubMedCentralCrossRef
3.
Tan, T.Y., L. Zhang, and C.P. Lim. 2019. Intelligent skin cancer diagnosis using improved particle swarm optimization and deep learning models. Applied Soft Computing 84: 105725.CrossRef
4.
Saguil, A., S. Kane, M. Mercado, et al. 2017. Herpes zoster and postherpetic neuralgia: prevention and management. American Family Physician 96 (10): 656–663.PubMed
5.
6.
Fuxench, Z.C.C. 2020. Pain in atopic dermatitis: it’s time we addressed this symptom further. British Journal of Dermatology 182 (6): 1326–1327.PubMedCrossRef
7.
Maghfour, J., S. Ly, W. Haidari, et al. 2022. Treatment of keratosis pilaris and its variants: a systematic review. The Journal of Dermatological Treatment 33 (3): 1231–1242.PubMedCrossRef
8.
Arnold, M., D. Singh, M. Laversanne, et al. 2022. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatology 158 (5): 495–503.PubMedPubMedCentralCrossRef
9.
Falahat, R., P. Perez-Villarroel, A.W. Mailloux, et al. 2019. STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity. Cancer Immunology Research 7 (11): 1837–1848.PubMedPubMedCentralCrossRef
10.
Feng, Z., C. Zang, L. Zhang, et al. 2022. STING activation promotes inflammatory response and delays skin wound healing in diabetic mice. Biochemical and Biophysical Research Communications 611: 126–131.PubMedCrossRef
11.
Pyclik, M., J. Durslewicz, J.A. Papinska, et al. 2023. STING agonist-induced skin inflammation is exacerbated with prior systemic innate immune activation. International Journal of Molecular Sciences 24 (4): 4128.PubMedPubMedCentralCrossRef
12.
Hong, Z., J. Mei, H. Guo, et al. 2022. Intervention of cGAS-STING signaling in sterile inflammatory diseases. Journal of Molecular Cell Biology 14 (2): mjac005.PubMedPubMedCentralCrossRef
13.
Chen, Q., L. Sun, and Z.J. Chen. 2016. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nature Immunology 17 (10): 1142–1149.PubMedCrossRef
14.
Skopelja-Gardner, S., J. An, and K.B. Elkon. 2022. Role of the cGAS-STING pathway in systemic and organ-specific diseases. Nature Reviews. Nephrology 18 (9): 558–572.PubMedPubMedCentralCrossRef
15.
Sun, L., J. Wu, F. Du, et al. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786–791.PubMedCrossRef
16.
Motwani, M., S. Pesiridis, and K.A. Fitzgerald. 2019. DNA Sensing by the cGAS-STING Pathway in Health and Disease. Nature Reviews Genetics 20 (11): 657–674.PubMedCrossRef
17.
Hopfner, K.P., and V. Hornung. 2020. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nature Reviews Molecular Cell Biology 21 (9): 501–521.PubMedCrossRef
18.
Li, X.D., J. Wu, D. Gao, et al. 2013. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341 (6152): 1390–1394.PubMedCrossRef
19.
Watson, R.O., S.L. Bell, D.A. MacDuff, et al. 2015. The cytosolic sensor cGAS detects Mycobacterium tuberculosis DNA to induce type i interferons and activate autophagy. Cell Host & Microbe 17 (6): 811–819.CrossRef
20.
21.
22.
Mackenzie, K.J., P. Carroll, C.A. Martin, et al. 2017. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548 (7668): 461–465.PubMedPubMedCentralCrossRef
23.
Zhang, X., J. Wu, F. Du, et al. 2014. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch like conformational changes in the activation loop. Cell Reports 6 (3): 421–430.PubMedCrossRef
24.
Li, X., C. Shu, G. Yi, et al. 2013. Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity 39 (6): 1019–1031.PubMedCrossRef
25.
Zhang, X., H. Shi, J. Wu, et al. 2013. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Molecular Cell 51 (2): 226–235.PubMedCrossRef
26.
Wu, J., L. Sun, X. Chen, et al. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339 (6121): 826–830.PubMedCrossRef
27.
Ablasser, A., M. Goldeck, T. Cavlar, et al. 2013. cGAS produces a 2’-5’-linked cyclic dinucleotide second messenger that activates STING. Nature 498 (7454): 380–384.PubMedPubMedCentralCrossRef
28.
Shang, G., C. Zhang, Z.J. Chen, et al. 2019. Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP. Nature 567 (7748): 389–393.PubMedPubMedCentralCrossRef
29.
Tanaka, Y., and Z.J. Chen. 2012. STING specifies IRF3 phosphorylation by TBK1 in the Cytosolic DNA signaling pathway. Science Signaling 5 (214): ra20.PubMedPubMedCentralCrossRef
30.
Liu, S., X. Cai, J. Wu, et al. 2015. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347 (6227): aaa2630.PubMedCrossRef
31.
Haag, S.M., M.F. Gulen, L. Reymond, et al. 2018. Targeting STING with covalent small-molecule inhibitors. Nature 559 (7713): 269–273.PubMedCrossRef
32.
33.
Abe, T., and G.N. Barber. 2014. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. Journal of Virology 88 (10): 5328–5341.PubMedPubMedCentralCrossRef
34.
Mizutani, Y., A. Kanbe, H. Ito, et al. 2020. Activation of STING signaling accelerates skin wound healing. Journal of Dermatological Science 97 (1): 21–29.PubMedCrossRef
35.
Beck, M.A., H. Fischer, L.M. Grabner, et al. 2021. DNA hypomethylation leads to cGAS-induced autoinflammation in the epidermis. EMBO Journal 40 (22): e108234.PubMedPubMedCentralCrossRef
36.
Wu, T., J. Gao, W. Liu, et al. 2021. NLRP3 protects mice from radiation-induced colon and skin damage via attenuating cGAS-STING signaling. Toxicology and Applied Pharmacology 418: 115495.PubMedCrossRef
37.
Zhou, M., X. Cheng, W. Zhu, et al. 2022. Activation of cGAS-STING pathway - A possible cause of myofiber atrophy/necrosis in dermatomyositis and immune-mediated necrotizing myopathy. Journal of Clinical Laboratory Analysis 36 (10): e24631.PubMedPubMedCentralCrossRef
38.
Zhang, L.J. 2019. Type1 Interferons Potential initiating factors linking skin wounds with psoriasis pathogenesis. Frontiers in Immunology 10: 1440.PubMedPubMedCentralCrossRef
39.
Pan, Y., Y. You, L. Sun, et al. 2021. The STING antagonist H-151 ameliorates psoriasis via suppression of STING/NF-kB-mediated inflammation. British Journal of Pharmacology 178 (24): 4907–4922.PubMedCrossRef
40.
Yu, Y., X. Xue, W. Tang, et al. 2022. Cytosolic DNA-mediated STING-dependent inflammation contributes to the progression of psoriasis. The Journal of Investigative Dermatology 142 (3): 898–906.PubMedCrossRef
41.
Li, X., Z. Zhang, Y. Yu, et al. 2022. Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus. Journal of Cellular and Molecular Medicine 26 (8): 2139–2151.CrossRef
42.
Nakamizo, S., G. Egawa, T. Honda, et al. 2015. Commensal bacteria and cutaneous immunity. Seminars in Immunopathology 37 (1): 73–80.PubMedCrossRef
43.
Bjerre, R.D., J. Bandier, L. Skov, et al. 2017. The role of the skin microbiome in atopic dermatitis: a systematic review. British Journal of Dermatology 177 (5): 1272–1278.PubMedCrossRef
44.
O’Neill, A.M., and R.L. Gallo. 2018. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 6 (1): 177.PubMedPubMedCentralCrossRef
45.
Wang, S., R. Wang, Y. Song, et al. 2022. Dysbiosis of nail microbiome in patients with psoriasis. Experimental Dermatology 31 (5): 800–806.PubMedCrossRef
46.
Lima-Junior, D.S., S.R. Krishnamurthy, N. Bouladoux, et al. 2021. Endogenous retroviruses promote homeostatic and inflammatory responses to the microbiota. Cell 184 (14): 3794–3811.PubMedPubMedCentralCrossRef
47.
Skudalski, L., R. Waldman, P.E. Kerr, et al. 2022. Melanoma: an update on systemic therapies. JAMA Dermatology 86 (3): 515–524.
48.
Xia, T., H. Konno, and G.N. Barber. 2016. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Research 76 (22): 6747–6759.PubMedCrossRef
49.
Falahat, R., A. Berglund, R.M. Putney, et al. 2021. Epigenetic reprogramming of tumor cell–intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proceedings of the National Academy of Sciences 118 (15): e2013598118.CrossRef
50.
Xu, T., J. Dai, L. Tang, et al. 2022. EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma. The Journal of Investigative Dermatology 142 (4): 1158–1170.PubMedCrossRef
51.
Woo, S.R., M.B. Fuertes, L. Corrales, et al. 2014. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (5): 830–842.PubMedPubMedCentralCrossRef
52.
Hu, M., M. Zhou, X. Bao, et al. 2021. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. The Journal of Clinical Investigation 131 (3): e139333.PubMedPubMedCentralCrossRef
53.
Shae, D., K.W. Becker, P. Christov, et al. 2019. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nature Nanotechnology 14 (3): 269–278.PubMedPubMedCentralCrossRef
54.
Ma, Z., Q. Xiong, H. Xia, et al. 2021. Carboplatin activates the cGAS-STING pathway by upregulating the TREX-1 (three prime repair exonuclease 1) expression in human melanoma. Bioengineered 12 (1): 6448–6458.PubMedPubMedCentralCrossRef
55.
Wang, Z., and E. Celis. 2015. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunology, Immunotherapy 64 (8): 1057–1066.PubMedCrossRef
56.
Nakamura, T., H. Miyabe, M. Hyodo, et al. 2015. Liposomes loaded with a sting pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. Journal of Controlled Release 216: 149–157.PubMedCrossRef
57.
Long, G.V., D. Stroyakovskiy, H. Gogas, et al. 2014. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New England Journal of Medicine 371 (20): 1877–1888.PubMedCrossRef
58.
Dulgar, O., T. Kutuk, and Z. Eroglu. 2021. Mechanisms of resistance to BRAF-targeted melanoma therapies. American Journal of Clinical Dermatology 22 (1): 1–10.PubMedCrossRef
59.
Yue, J., R. Vendramin, F. Liu, et al. 2020. Targeted chemotherapy overcomes drug resistance in melanoma. Genes & Development 34 (9–10): 637–649.CrossRef
60.
Cesi, G., G. Walbrecq, A. Zimmer, et al. 2017. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Molecular Cancer 16 (1): 102.PubMedPubMedCentralCrossRef
61.
Khamari, R., A. Trinh, P.E. Gabert, et al. 2018. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death & Disease 9 (3): 325.CrossRef
62.
Hos, N.J., R. Ganesan, S. Gutiérrez, et al. 2017. Type I interferon enhances necroptosis of Salmonella Typhimurium–infected macrophages by impairing antioxidative stress responses. Journal of Cell Biology 216 (12): 4107–4121.PubMedPubMedCentralCrossRef
63.
Ramanjulu, J.M., G.S. Pesiridis, J. Yang, et al. 2018. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564 (7736): 439–443.PubMedCrossRef
64.
Chipurupalli, S., R. Ganesan, S.P. Dhanabal, et al. 2020. Pharmacological STING activation is a potential alternative to overcome drug-resistance in melanoma. Frontiers in Oncology 10: 758.PubMedPubMedCentralCrossRef
65.
Larkin, J., V. Chiarion-Sileni, R. Gonzalez, et al. 2019. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 381 (16): 1535–1546.PubMedCrossRef
66.
67.
Nguyen, T.T., L. Ramsay, M. Ahanfeshar-Adams, et al. 2021. Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment. Clinical Cancer Research 27 (12): 3432–3442.PubMedCrossRef
68.
Srour, N., O.D. Villarreal, S. Hardikar, et al. 2022. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell Reports 38 (13): 110582.PubMedCrossRef
69.
Yum, S., M. Li, A.E. Frankel, et al. 2019. Roles of the cGAS-STING pathway in cancer immunosurveillance and immunotherapy. Annual Review of Cancer Biology 3: 323–344.CrossRef
70.
Sato, S., Y. Sawada, and M. Nakamura. 2021. STING signaling and skin cancers. Cancers (Basel) 13 (22): 5603.PubMedCrossRef
71.
Miyabe, H., M. Hyodo, T. Nakamura, et al. 2014. A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy. Journal of Controlled Release 184: 20–27.PubMedCrossRef
72.
Nakamura, T., T. Sato, R. Endo, et al. 2021. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. Journal for Immunotherapy of Cancer 9 (7): e002852.PubMedPubMedCentralCrossRef
73.
Lama, L., C. Adura, W. Xie, et al. 2019. Development of human cGAS-specific small molecule inhibitors for repression of dsDNA triggered interferon expression. Nature Communications 10 (1): 2261.PubMedPubMedCentralCrossRef
74.
Vincent, J., C. Adura, P. Gao, et al. 2017. Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nature Communications 8 (1): 750.PubMedPubMedCentralCrossRef
75.
Wiser, C., B. Kim, J. Vincent, et al. 2020. Small molecule inhibition of human cGAS reduces total cGAMP output and cytokine expression in cells. Science and Reports 10 (1): 7604.CrossRef
76.
Tan, J., B. Wu, T. Chen, et al. 2021. Synthesis and pharmacological evaluation of tetrahydro-γ-carboline derivatives as potent anti-inflammatory agents targeting cyclic GMP-AMP synthase. Journal of Medicinal Chemistry 64 (11): 7667–7690.PubMedCrossRef
77.
Platt, B., E. Belarski, J. Manaloor, et al. 2020. Comparison of risk of recrudescent fever in children with Kawasaki disease treated with intravenous immunoglobulin and low-dose vs high-dose aspirin. JAMA Network Open 3 (1): e1918565.PubMedPubMedCentralCrossRef
78.
D’Orazio, J.A. 2021. Aspirin’s protective effects highlight the role of inflammation in UV-induced skin damage and carcinogenesis. The Journal of Investigative Dermatology 141 (1): 10–11.PubMedCrossRef
79.
80.
Opoku-Temeng, C., and H.O. Sintim. 2016. Potent inhibition of cyclic diadenylate monophosphate cyclase by the antiparasitic drug, suramin. Chemical Communications (Cambridge, England) 52 (19): 3754–3757.PubMedCrossRef
81.
Wang, M., M.A. Sooreshjani, C. Mikek, et al. 2018. Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels. Future Medicinal Chemistry 10 (11): 1301–1317.PubMedCrossRef
82.
Steinhagen, F., T. Zillinger, K. Peukert, et al. 2018. Suppressive oligodeoxynucleotides containing TTAGGG motifs Inhibit cGAS activation in human monocytes. European Journal of Immunology 48 (4): 605–611.PubMedCrossRef
83.
Li, Q., Y. Cao, C. Dang, et al. 2020. Inhibition of double-strand DNA-sensing cGAS ameliorates brain injury after ischemic stroke. EMBO Molecular Medicine 12 (4): e11002.PubMedPubMedCentralCrossRef
84.
Chu, L., C. Li, Y. Li, et al. 2021. Perillaldehyde inhibition of cGAS reduces dsDNA-induced interferon response. Frontiers in Immunology 12: 655637.PubMedPubMedCentralCrossRef
85.
Liu, Z.S., H. Cai, W. Xue, et al. 2019. G3BP1 promotes DNA binding and activation of cGAS. Nature Immunology 20 (1): 18–28.PubMedCrossRef
86.
Cai, H., X. Liu, F. Zhang, et al. 2021. G3BP1 inhibition alleviates intracellular nucleic acid-induced autoimmune responses. The Journal of Immunology 206 (10): 2453–2467.PubMedCrossRef
87.
Valentin, R., C. Wong, A.S. Alharbi, et al. 2021. Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2’-O-methyl gapmer oligonucleotides. Nucleic Acids Research 49 (11): 6082–6099.PubMedPubMedCentralCrossRef
88.
Cuddy, S.R., A.R. Schinlever, S. Dochnal, et al. 2020. Neuronal hyperexcitability is a DLK-dependent trigger of herpes simplex virus reactivation that can be induced by IL-1. eLife 9: e58037.PubMedPubMedCentralCrossRef
89.
Guellil, M., L. van Dorp, S.A. Inskip, et al. 2022. Ancient herpes simplex 1 genomes reveal recent viral structure in Eurasia. Science Advances 8 (30): eabo4435.PubMedPubMedCentralCrossRef
90.
Cerón, S., B.J. North, S.A. Taylor, et al. 2019. The STING agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA) stimulates an antiviral state and protects mice against herpes simplex virus. Virology 529: 23–28.PubMedCrossRef
91.
Zhu, Q., H. Hu, H. Liu, et al. 2020. A synthetic STING agonist inhibits the replication of human parainfluenza virus 3 and rhinovirus 16 through distinct mechanisms. Antiviral Research 183: 104933.PubMedPubMedCentralCrossRef
92.
93.
Demaria, O., A. De Gassart, S. Coso, et al. 2015. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proceedings of the National Academy of Sciences 112 (50): 15408–15413.CrossRef
94.
Yang, H., W.S. Lee, S.J. Kong, et al. 2019. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. The Journal of Clinical Investigation 129 (10): 4350–4364.PubMedPubMedCentralCrossRef
95.
Wang, H., S. Hu, X. Chen, et al. 2017. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proceedings of the National Academy of Sciences 114 (7): 1637–1642.CrossRef
96.
97.
Vonderhaar, E.P., N.S. Barnekow, D. McAllister, et al. 2021. STING activated tumor-intrinsic type I interferon signaling promotes CXCR3 dependent antitumor immunity in pancreatic cancer. Cellular and Molecular Gastroenterology and Hepatology 12 (1): 41–58.PubMedPubMedCentralCrossRef
98.
Berger, G., E.H. Knelson, J.L. Jimenez-Macias, et al. 2022. STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models. Proceedings of the National Academy of Sciences 119 (28): e2111003119.CrossRef
99.
Meric-Bernstam, F., R.F. Sweis, F.S. Hodi, et al. 2022. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clinical Cancer Research 28 (4): 677–688.PubMedCrossRef
100.
Chelvanambi, M., R.J. Fecek, J.L. Taylor, et al. 2021. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Journal for Immunotherapy of Cancer 9 (2): e001906.PubMedPubMedCentralCrossRef
101.
Ager, C.R., A. Boda, K. Rajapakshe, et al. 2021. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Journal for Immunotherapy of Cancer 9 (8): e003246.PubMedPubMedCentralCrossRef
102.
Ager, C.R., H. Zhang, Z. Wei, et al. 2019. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorganic & Medicinal Chemistry Letters 29 (20): 126640.CrossRef
103.
104.
Jing, W., D. McAllister, E.P. Vonderhaar, et al. 2019. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. Journal for Immunotherapy of Cancer 7 (1): 115.PubMedPubMedCentralCrossRef
105.
Corrales, L., L.H. Glickman, S.M. McWhirter, et al. 2015. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports 11 (7): 1018–1030.PubMedCrossRef
106.
Pan, B.S., S.A. Perera, J.A. Piesvaux, et al. 2020. An orally available non-nucleotide STING agonist with antitumor activity. Science 369 (6506): eaba6098.PubMedCrossRef
107.
Tian, J., D. Zhang, V. Kurbatov, et al. 2021. 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING. EMBO Journal 40 (7): e106065.PubMedPubMedCentralCrossRef
108.
McAndrews, K.M., S.P.Y. Che, V.S. LeBleu, et al. 2021. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity. Journal of Biological Chemistry 296: 100523.PubMedPubMedCentralCrossRef
109.
Li, S., M. Luo, Z. Wang, et al. 2021. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nature Biomedical Engineering 5 (5): 455–466.PubMedPubMedCentralCrossRef
110.
Zhou, Q., Y. Zhou, T. Li, et al. 2021. Nanoparticle-mediated STING agonist delivery for enhanced cancer immunotherapy. Macromolecular Bioscience 21 (8): e2100133.PubMedCrossRef
111.
Cheng, N., R. Watkins-Schulz, R.D. Junkins, et al. 2018. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer. JCI Insight 3 (22): e120638.PubMedPubMedCentralCrossRef
112.
Li, K., Y. Ye, L. Liu, et al. 2021. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma. Biomaterials Science 9 (3): 765–773.PubMedCrossRef
113.
Zheng, H., B. Guo, X. Qiu, et al. 2022. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy. Bioactive Materials 16: 1–11.PubMedPubMedCentralCrossRef
114.
Dane, E.L., A. Belessiotis-Richards, C. Backlund, et al. 2022. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer Immunity. Nature Materials 21 (6): 710–720.PubMedPubMedCentralCrossRef
115.
Zhang, K., C. Qi, and K. Cai. 2022. Manganese-based tumor immunotherapy. Advanced Materials, e2205409.
116.
Wang, C., Y. Guan, M. Lv, et al. 2018. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity 48 (4): 675–687.PubMedCrossRef
117.
Hou, L., C. Tian, Y. Yan, et al. 2020. Manganese-based nanoactivator optimizes cancer immunotherapy via enhancing innate immunity. ACS Nano 14 (4): 3927–3940.PubMedCrossRef
118.
Chen, C., Y. Tong, Y. Zheng, et al. 2021. Cytosolic delivery of thiolated Mn-cGAMP nanovaccine to enhance the antitumor immune responses. Small (Weinheim an der Bergstrasse, Germany) 17 (17): e2006970.PubMedCrossRef
119.
Gao, M., Y. Xie, K. Lei, et al. 2021. A manganese phosphate nanocluster activates the cGAS-STING pathway for enhanced cancer immunotherapy. Advanced Therapeutics 4 (8): 2100065.CrossRef
120.
Lv, M., M. Chen, R. Zhang, et al. 2020. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Research 30 (11): 966–979.PubMedPubMedCentralCrossRef
121.
Decout, A., J.D. Katz, S. Venkatraman, et al. 2021. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nature Reviews Immunology 21 (9): 548–569.PubMedPubMedCentralCrossRef
122.
Gong, W., L. Lu, Y. Zhou, et al. 2021. The novel STING antagonist H151 ameliorates cisplatin-induced acute kidney injury and mitochondrial dysfunction. American Journal of Physiology-Renal Physiology 320 (4): 608–616.CrossRef
123.
Domizio, J.D., M.F. Gulen, F. Saidoune, et al. 2022. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 603 (7899): 145–151.PubMedPubMedCentralCrossRef
124.
Li, S., Z. Hong, Z. Wang, et al. 2018. The cyclopeptide astin C specifically inhibits the innate immune CDN sensor STING. Cell Reports 25 (12): 3405–3421.PubMedCrossRef
125.
Prabakaran, T., A. Troldborg, S. Kumpunya, et al. 2021. A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology. eBioMedicine 66: 103314.PubMedPubMedCentralCrossRef
126.
Hong, Z., J. Mei, C. Li, et al. 2021. STING inhibitors target the cyclic dinucleotide binding pocket. Proceedings of the National Academy of Sciences 118 (24): e2105465118.CrossRef
127.
Siu, T., M.D. Altman, G.A. Baltus, et al. 2018. Discovery of a novel cGAMP competitive ligand of the inactive form of STING. ACS Medicinal Chemistry Letters 10 (1): 92–97.PubMedPubMedCentralCrossRef
128.
Harabuchi, S., A. Kosaka, Y. Yajima, et al. 2020. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. Biochemical and Biophysical Research Communications 522 (2): 408–414.PubMedCrossRef
129.
Hayman, T.J., M. Baro, T. MacNeil, et al. 2021. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 12 (1): 2327.PubMedPubMedCentralCrossRef
130.
Krump, N.A., R. Wang, W. Liu, et al. 2021. Merkel cell polyomavirus infection induces an antiviral innate immune response in human dermal fibroblasts. Journal of Virology 95 (13): e0221120.PubMedCrossRef
131.
Liu, W., G.B. Kim, N.A. Krump, et al. 2020. Selective reactivation of STING signaling to target Merkel cell carcinoma. Proceedings of the National Academy of Sciences 117 (24): 13730–13739.CrossRef
Metadaten
Titel
The Crucial Roles and Research Advances of cGAS-STING Pathway in Cutaneous Disorders
verfasst von
Cong Huang
Wenting Li
Xuanyao Ren
Mindan Tang
Kaoyuan Zhang
Fan Zhuo
Xia Dou
Bo Yu
Publikationsdatum
21.04.2023
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-023-01812-7

Weitere Artikel der Ausgabe 4/2023

Inflammation 4/2023 Zur Ausgabe

CORRESPONDENCE

LPS-aggravated Ferroptosis via Disrupting Circadian Rhythm by Bmal1/AKT/p53 in Sepsis-Induced Myocardial Injury

RESEARCH

NF-κB-Inducing Kinase Provokes Insulin Resistance in Skeletal Muscle of Obese Mice

RESEARCH

Increased n-6 Polyunsaturated Fatty Acids Indicate Pro- and Anti-Inflammatory Lipid Modifications in Synovial Membranes with Rheumatoid Arthritis

ORIGINAL ARTICLE

Identification of CCL20 as a Key Biomarker of Inflammatory Responses in the Pathogenesis of Intracerebral Hemorrhage

RESEARCH

Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2

RESEARCH

Decreased Imiquimod-Induced Psoriasis-Like Skin Inflammation in a Novel MvdF250S/+ Knock-In Mouse Model

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise